Tryngolza (olezarsen) — United Healthcare

Initial criteria

• Diagnosis of familial chylomicronemia syndrome (FCS) (i.e., monogenic chylomicronemia, type 1 hyperlipoproteinemia)

Reauthorization criteria

• Documentation of positive clinical response to Tryngolza therapy (e.g., reduction in triglycerides, reduction in episodes of acute pancreatitis)

Approval duration

12 months